00976nas a2200133   4500000000100000008004100001100001200042700001300054245008000067856007500147300001200222490000600234520060200240       2020                            d1 aBhat RM1 aVaidya T00aWhat is new in the pathogenesis and management of erythema nodosum leprosum  uhttp://www.idoj.in/temp/IndianDermatolOnlineJ114482-3755472_102554.pdf  a482-4920 v43 aErythema nodosum leprosum (ENL) is a manifestation of type II lepra reaction, seen in lepromatous or borderline lepromatous leprosy. Although it is a common reaction encountered in clinical practice, there are an increasingly large number of newer updates in the pathophysiology and management of this condition.The treatment options have expanded far beyond just thalidomide and steroids and now extends to TNF-α inhibitors, thalidomide analogs, tenidap, cyclosporine A, plasma exchange, and even IVIG amongst others. These updates and the current knowledge of ENL are summarized in this review.